Get the Stockscreener App
12.17
14.24%
-2.02
Alto Neuroscience Inc stock is traded at $12.17, with a volume of 782.11K.
It is down -14.24% in the last 24 hours and up +76.63% over the past month.
Alto Neuroscience Inc is a clinical-stage biopharmaceutical company with a mission to redefine psychiatry by leveraging individuals' neurobiology to develop personalized and effective treatment options. The company currently consists of different clinical-stage assets such as ALTO-100, ALTO-202, ALTO-101, and ALTO-300 among others initially targeting depressive disorders and schizophrenia populations as identified by independent brain-based biomarkers.
See More
Previous Close:
$14.19
Open:
$14.19
24h Volume:
782.11K
Relative Volume:
0.53
Market Cap:
$329.52M
Revenue:
-
Net Income/Loss:
$-49.81M
P/E Ratio:
-5.6447
EPS:
-2.156
Net Cash Flow:
$-42.93M
1W Performance:
-0.65%
1M Performance:
+76.63%
6M Performance:
+398.77%
1Y Performance:
+205.78%
1-Day Range:
$11.81
$14.20
1-Week Range:
$11.73
$15.18
52-Week Range:
$1.60
$15.18
Alto Neuroscience Inc Stock (ANRO) Company Profile
Name
Alto Neuroscience Inc
Sector
Industry
Phone
773-255-5012
Address
650 CASTRO STREET, SUITE 450, MOUNTAIN VIEW
Compare ANRO with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ANRO
Alto Neuroscience Inc
|
12.17 | 438.60M | 0 | -49.81M | -42.93M | -2.156 |
|
VRTX
Vertex Pharmaceuticals Inc
|
426.00 | 109.11B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
642.25 | 68.50B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
434.07 | 60.25B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
826.28 | 50.39B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
186.23 | 40.44B | 447.02M | -1.18B | -868.57M | -6.1812 |
Alto Neuroscience Inc Stock (ANRO) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Sep-29-25 | Initiated | Chardan Capital Markets | Buy |
| Oct-23-24 | Downgrade | Rodman & Renshaw | Buy → Neutral |
| Oct-23-24 | Downgrade | Wedbush | Outperform → Neutral |
| Sep-03-24 | Initiated | Wedbush | Outperform |
| Feb-27-24 | Initiated | Jefferies | Buy |
| Feb-27-24 | Initiated | Robert W. Baird | Outperform |
| Feb-27-24 | Initiated | Stifel | Buy |
| Feb-27-24 | Initiated | TD Cowen | Outperform |
| Feb-27-24 | Initiated | William Blair | Outperform |
View All
Alto Neuroscience Inc Stock (ANRO) Latest News
Can Alto Neuroscience Inc. stock test all time highs2025 Breakouts & Breakdowns & Weekly Market Pulse Updates - newser.com
Is Alto Neuroscience Inc. stock gaining market shareGap Down & Entry and Exit Point Strategies - newser.com
Will Alto Neuroscience Inc. stock recover faster than marketShort Setup & Accurate Entry/Exit Alerts - newser.com
Key resistance and support levels for Alto Neuroscience Inc.2025 Dividend Review & Free Real-Time Market Sentiment Alerts - newser.com
Price action breakdown for Alto Neuroscience Inc.July 2025 Analyst Calls & Free Fast Gain Swing Trade Alerts - newser.com
Quantitative breakdown of Alto Neuroscience Inc. recent move2025 Sector Review & High Yield Stock Recommendations - newser.com
Relative strength of Alto Neuroscience Inc. in sector analysis2025 Investor Takeaways & Long-Term Safe Investment Plans - newser.com
What earnings revisions data tells us about Alto Neuroscience Inc.Portfolio Return Summary & High Conviction Investment Ideas - newser.com
Risk adjusted return profile for Alto Neuroscience Inc. analyzedTrade Exit Report & Technical Entry and Exit Alerts - newser.com
What the charts say about Alto Neuroscience Inc. todayEarnings Beat & Free Community Consensus Stock Picks - newser.com
Can Alto Neuroscience Inc. hit a new high this monthQuarterly Profit Report & AI Powered Market Entry Ideas - newser.com
What indicators show strength in Alto Neuroscience Inc.July 2025 Analyst Calls & Weekly Chart Analysis and Trade Guides - newser.com
Chart based exit strategy for Alto Neuroscience Inc.Long Setup & Consistent Income Trade Ideas - newser.com
Why Alto Neuroscience Inc. stock gets analyst attentionJuly 2025 Earnings & Expert Verified Movement Alerts - newser.com
How risky is Alto Neuroscience Inc. stock nowVolume Spike & Fast Exit Strategy with Risk Control - newser.com
Is Alto Neuroscience Inc. stock a buy during volatile marketsTrade Ideas & AI Optimized Trading Strategy Guides - newser.com
Can Alto Neuroscience Inc. stock outperform in 2025 bull marketEarnings Summary Report & Long-Term Capital Growth Ideas - newser.com
When is the best time to exit Alto Neuroscience Inc.Dollar Strength & Short-Term Trading Alerts - newser.com
How to track smart money flows in Alto Neuroscience Inc.July 2025 Gainers & Safe Entry Trade Signal Reports - newser.com
Alto Neuroscience, Inc. (NYSE:ANRO) Given Average Rating of "Moderate Buy" by Analysts - MarketBeat
What data driven models say about Alto Neuroscience Inc.’s futureMarket Risk Summary & Daily Profit Focused Screening - newser.com
Can Alto Neuroscience Inc. stock sustain free cash flow growth2025 Performance Recap & Free Technical Confirmation Trade Alerts - newser.com
What makes Alto Neuroscience Inc. stock attractive to growth funds2025 Major Catalysts & Technical Entry and Exit Tips - newser.com
COMMODORE CAPITAL LP Acquires Significant Stake in Alto Neuroscience Inc - GuruFocus
Will Alto Neuroscience Inc. stock maintain growth storyMarket Performance Report & Daily Market Momentum Tracking - newser.com
Is Alto Neuroscience Inc. trending in predictive chart modelsWatch List & Daily Stock Trend Watchlist - newser.com
Why retail investors pile into Alto Neuroscience Inc. stock2025 Institutional Moves & Consistent Growth Stock Picks - newser.com
Will Alto Neuroscience Inc. stock go up soonMarket Volume Summary & Low Drawdown Momentum Trade Ideas - newser.com
What institutional flow reveals about Alto Neuroscience Inc.Weekly Trade Report & Safe Capital Growth Plans - newser.com
Alto Neuroscience Inc Stock (ANRO) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.64%
0.35%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):